Skip to main content
    P

    Pharvaris BV (PHVS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $32.44
    -0.92 (-2.76%)

    Market Cap: $2.36B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Pharvaris BV (PHVS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in EUR.

    Pharvaris BV reported revenue of EUR 0 for the fiscal year ended Dec 31, 2025. That year, net income was EUR -175.70M, operating cash flow was EUR -137.07M and free cash flow was EUR -137.24M. The quarter ended Sep 30, 2026 had revenue of EUR 0 and net income of EUR -47.41M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of EUR 169.82M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 20250N/AN/AN/AN/A
    Dec 20240N/AN/AN/AN/A
    Dec 20230N/AN/AN/AN/A
    Dec 20220N/AN/AN/AN/A
    Dec 20210N/AN/AN/AN/A
    Dec 20200N/AN/AN/AN/A
    Dec 20190N/AN/AN/AN/A
    Dec 20180N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Cost of revenueN/AN/A252.27K150.19K80.46KN/AN/AN/A
    Gross profitN/AN/A-252.27K-150.19K-80.46KN/AN/AN/A
    Research and development124.48M98.56M65.58M57.38M35.79M22.24M6.36M3.65M
    Operating income-169.82M-145.69M-96.91M-86.71M-54.14M-28.51M-8.97M-4.31M
    Net income-175.70M-134.22M-100.88M-76.33M-42.73M-29.62M-8.98M-4.31M
    EBITDAN/A-145.42MN/A-86.56M-42.31MN/AN/AN/A
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profitN/A-182.27K-106.45KN/AN/AN/A-97.02KN/AN/A-69.02K-71.00KN/A
    Operating income-50.08M-50.79M-45.00M-47.60M-39.66M-40.37M42.19M-45.09M-37.90M-34.38M-28.31M-27.18M
    Net income-47.41M-47.84M-39.85M-46.74M-37.14M-45.48M-46.34M-34.76M-41.71M-29.73M-28.02M-32.75M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of EUR 200.21K by 291.48M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets301.45M291.37M398.69M167.73M212.09M101.10M20.60M5.43M4.80M
    Current assets299.17M289.42M397.85M166.85M211.57M100.95M20.58M5.43M4.80M
    Cash and equivalents291.68M280.73M391.23M161.84M209.35M98.63M20.33M5.39M4.80M
    Total liabilities30.18M23.61M14.65M18.47M7.14M5.31M1.92M481.34K138.84K
    Short-term debt200.21K222.43K195.34K187.40K99.43KN/AN/AN/AN/A
    Shareholder equity271.27M267.76M384.05M149.26M204.95M95.79M18.67M4.95M4.66M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets295.06M328.67M259.79M301.45M338.90M209.81M248.06M291.37M313.18M351.85M377.60M398.69M
    Total liabilities30.09M27.86M23.46M30.18M26.66M25.47M22.73M23.61M16.39M19.08M18.43M14.65M
    Cash and equivalents282.73M318.28M246.96M291.68M329.29M199.57M236.50M280.73M305.19M343.57M368.34M391.23M
    Shareholder equity264.97M300.81M236.33M271.27M312.24M184.34M225.34M267.76M296.79M332.77M359.17M384.05M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-137.07M-120.13M-93.05M-67.16M-44.60M-21.50M-6.68M-3.92M
    Capital expenditures164.62K538.09K89.98K124.30K130.03K42.98K13.48K13.48K
    Free cash flow-137.24M-120.67M-93.14M-67.29M-44.73M-21.54M-6.69M-3.93M
    Investing cash flow-164.62K-538.09K-89.98K-124.30K-130.03K-42.98K-13.48K-13.48K
    Financing cash flow160.61M2.68M325.39M8.65M143.67M101.20M21.63M4.51M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-42.22M-37.80M-49.57M-37.95M-30.67M-29.98M-38.47M-34.95M-33.26M-27.68M-24.23M-23.81M
    Capital expenditures026.91K52.95K1.54K18.71K16.64K161.00K160.92K306.32K40.14K30.71K28.38K
    Free cash flow-42.22M-37.83M-49.62M-37.95M-30.69M-30.00M-38.63M-35.11M-33.57M-27.72M-24.26M-23.84M
    Last 12 quarters

    Frequently Asked Questions About PHVS

    What is Pharvaris BV's annual revenue?

    Pharvaris BV reported revenue of EUR 0 for the fiscal year ended Dec 31, 2025.

    Is Pharvaris BV profitable?

    No. Pharvaris BV reported net income of EUR -175.70M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PHVS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -137.07M minus capital expenditures of EUR 164.62K produced free cash flow of EUR -137.24M.

    How much debt does Pharvaris BV have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of EUR 200.21K and cash and equivalents of EUR 291.68M.